ImmunoCellular Therapeutics (IMUCD) Stock Price, News & Analysis

Company Overview

ImmunoCellular Therapeutics, Ltd. was a biotechnology company focused on developing immunotherapies for cancer. Its research centered on vaccines designed to stimulate a patient’s immune system to recognize and attack tumor cells, particularly in difficult-to-treat solid tumors.

The company’s lead investigational product was ICT-107, an autologous dendritic-cell vaccine developed for glioblastoma, an aggressive form of brain cancer. ImmunoCellular also pursued ICT-121, a cancer-stem-cell vaccine candidate, and ICT-140, an investigational vaccine for ovarian cancer. These products were experimental therapies and were not broadly marketed medicines.

ImmunoCellular Therapeutics operated as a development-stage biotechnology company and advanced its programs through clinical research rather than through an established commercial product portfolio. Publicly available information about its later operations, current activities, and leadership is limited.

Key Stats

• Today's Range: $0.08 to $0.08
• 50-Day Range: $0.08 to $0.20
• 52-Week Range: $0.16 to $0.51
• Volume: 1 shs
• Average Volume: 6,605 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:IMUCD
• CIK: N/A
• Web: eompharma.com
• Phone: (818) 264-2300
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.63